What are the functions of Evantumumab/Carestream?

As a new generation of targeted drugs, amivantamab (amivantamab) exhibits multi-faceted functions due to its unique design of bispecific antibodies. It simultaneously acts on EGFR and MET, two signaling pathways closely related to tumor growth and drug resistance, so it can more comprehensively inhibit non-small cell lung cancer. At the functional level, evantumumab is mainly reflected in three aspects.

First, directly inhibit the growth of tumor cells. By blocking the EGFR and MET signaling pathways, the drug can inhibit cell proliferation and differentiation and reduce the escape pathways of cancer cells. It can still play a role, especially in the case of traditional EGFR-TKI resistance. Second, enhance the body’s immune response. In addition to directly inhibiting tumors, evantumumab can also help the body eliminate cancer cells more effectively by mobilizing the activity of natural killer cells and promoting antibody-dependent cytotoxic reactions. This means that it has both targeting and immune mechanisms. Third, improve clinical symptoms and delay disease progression. For symptoms such as respiratory discomfort and fatigue caused by lung cancer, evantumumab can indirectly alleviate symptoms in some patients by controlling tumor shrinkage, thereby improving the quality of life.

In terms of indications, the application scope of evantumumab is constantly expanding. It has been approved in combination with lazertinib for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations. It can also be combined with the chemotherapy drugs carboplatin and pemetrexed as a first-line regimen for patients with EGFR exon 20 insertion mutations. In addition, evantumumab is also approved as monotherapy for patients with EGFR exon 20 mutations who have failed chemotherapy. In these applications, it has shown relatively long-lasting and stable efficacy.

In general, the function of evantumumab is not only reflected in the precise inhibition of molecular targets, but also in improving patients' quality of life and delaying the disease. It is an important achievement of modern targeted tumor therapy.

Reference materials:https://www.rybrevant.com/